Synthetic cannabinoids use in a sample of opioid-use disorder patients.
cannabis
new psychoactive substances
opioid use disorder
synthetic cannabinoid
urine sample analysis
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
05
2022
accepted:
18
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Cannabis is the most widely consumed illegal drug in the world and synthetic cannabinoids are increasingly gaining popularity and replacing traditional cannabis. These substances are a type of new psychoactive substance that mimics the cannabis effects but often are more severe. Since, people with opioids use disorder use widely cannabis, they are a population vulnerable to use synthetic cannabinoids. In addition, these substances are not detected by the standard test used in the clinical practice and drug-checking is more common in recreational settings. A cross-sectional study with samples of 301 opioid use disorder individuals was carried out at the addiction care services from Barcelona and Badalona. Urinalysis was performed by high-sensitivity gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography-high -resolution mass spectrometry (UHPLC-HRMS). Any synthetic cannabinoid was detected in 4.3% of the individuals and in 23% of these samples two or more synthetic cannabinoids were detected. Among the 8 different synthetic cannabinoids detected, most common were JWH-032 and JWH-122. Natural cannabis was detected in the 18.6% of the samples and only in the 0.7% of them THC was identified. Several different synthetic cannabinoids were detected and a non-negligible percentage of natural cannabis was detected among our sample. Our results suggest that the use of synthetic cannabinoids may be related to the avoidance of detection. In the absence of methods for the detection of these substances in clinical practice, there are insufficient data and knowledge making difficult to understand about this phenomenon among opioid use disorder population.
Identifiants
pubmed: 35990071
doi: 10.3389/fpsyt.2022.956120
pmc: PMC9381952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
956120Informations de copyright
Copyright © 2022 Alías-Ferri, Pellegrini, Marchei, Pacifici, Rotolo, Pichini, Pérez-Mañá, Papaseit, Muga, Fonseca, Farré and Torrens.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Addict Behav. 2021 Mar;114:106752
pubmed: 33348147
Hum Psychopharmacol. 2016 Jan;31(1):44-52
pubmed: 26763789
Biology (Basel). 2022 Apr 22;11(5):
pubmed: 35625373
Int J Mol Sci. 2020 Dec 10;21(24):
pubmed: 33321929
Front Psychiatry. 2020 Jul 07;11:569
pubmed: 32733288
J Anal Toxicol. 2021 Nov 24;:
pubmed: 34849994
Int J Mol Sci. 2020 Aug 25;21(17):
pubmed: 32854313
Crit Rev Toxicol. 2020 May;50(5):359-382
pubmed: 32530350
Eur Addict Res. 2022 Apr 4;:1-8
pubmed: 35378545
Int J Drug Policy. 2016 Jun;32:77-84
pubmed: 27184218
Front Pharmacol. 2021 Aug 19;12:705643
pubmed: 34489699
Addiction. 2003 Mar;98(3):269-79
pubmed: 12603227
Subst Abuse Treat Prev Policy. 2022 Feb 15;17(1):12
pubmed: 35168646
Drug Alcohol Depend. 2014 Nov 1;144:12-41
pubmed: 25220897
Front Psychiatry. 2020 May 25;11:464
pubmed: 32523555
Medicines (Basel). 2022 Mar 01;9(3):
pubmed: 35323718
Biology (Basel). 2021 Mar 24;10(4):
pubmed: 33805054
Med Clin North Am. 2018 Jul;102(4):697-714
pubmed: 29933824
Am J Emerg Med. 2022 Mar;53:150-153
pubmed: 35051702
Int J Med Sci. 2018 Aug 6;15(12):1286-1295
pubmed: 30275754
Curr Pharm Des. 2021 Nov 15;:
pubmed: 34781870
Int J Mol Sci. 2021 Apr 13;22(8):
pubmed: 33924438
Drug Alcohol Depend. 2019 May 1;198:28-33
pubmed: 30877954
Front Psychiatry. 2021 Apr 23;12:669921
pubmed: 33967865
Subst Abus. 2019;40(2):160-169
pubmed: 30457960